USPTO serial 76313158
MIRROR IMAGE
Reviewed by CopyMark Law Group
Reg. 2694903Status 710
- Filing date
- Status date
- Registration date
- Mar 11, 2003
- Examiner
- ESTRADA, LINDA M
- Law office
- SCANNING ON DEMAND
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with MIRROR IMAGE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
13355 Berlin, DE
13355 Berlin, DE
13355 Berlin, DE
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Lisa V. Mueller
LISA V MUELLER WOOD PHILLIPS KATZ CLARK & MORTIMERCITICORP CTR STE 3800500 W MADDISON STCHICAGO, IL 60661-2511Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical products, namely polynucleotides, preferably containing at least one L-nucleotide, polypeptides, preferably containing at least one D-amino acid, compounds consisting in whole or in part of nucleic acids or derivatives thereof, for industrial, scientific, agricultural, gardening and forestry purposes; D- and L- nucleotides for use in manufacturing pharmaceuticals; L- and D- amino acids for use in manufacturing pharmaceuticals | SECTION 8 - CANCELLED | — |
| 005 | Pharmaceutical and veterinary products, namely, preparations for sanitation, slimming, appetite suppressants, pharmaceuticals for acidosis therapeutics, analeptic and antihypoxaemics; analgetics and antirheumatic drugs, pharmaceuticals functioning as antihelmintics, antiallergics, antianemia drugs, antiarrhythmics, antibiotics and antiinfectives, antidementics, nootropics, antidiabetics, antidotes for the treatment of poisoning, antiemetics and antivertiginosics, antiepileptics, antihemorrhagics, antifibrinolyrics, hemostatics, antihypertonics, antihypoglycemics, antihypotonics, anticoagulants, antimycotics, pharmaceuticals functioning as antiparasitics, antiphlogistics, antitussives, expectorants for use in atherosclerosis, balneotherapeutics and pharmaceuticals for thermal therapy, pharmaceuticals functioning as beta receptor blocking agents, pharmaceuticals for calcium channel blocking and inhibiting of the renin angiotensin-system, pharmaceuticals functioning as broncholytics and antiasthmetics cholagoguegics and for use in biliary tract therapeutics; pharmaceuticals functioning as cholinergics, corticoids, dermatics; all purpose disinfectants and antiseptics; pharmaceuticals functioning as dietetic agents and in alimentary therapeutics; diagnostic preparations functioning as diuretics, as agents for favoring blood flow, as withdrawal agents, as fibrinolytics, to treat gout, the flu and catarrhal fever; pharmaceuticals for the treatment of gynecological illnesses, namely, menstrual cramps, hemorrhoids, hepatitis; pharmaceuticals functioning as hypnotics and sedatives; pharmaceuticals to treat cardiac ailments; pharmaceuticals for use in caries and parodontosis; dental preparations, namely, dental abrasives; laxatives, pharmaceuticals functioning as antilipaemics, local anaesthetics, neural therapeutics, gastro-intestinal preparations, pharmaceuticals to treat migraines; pharmaceutical preparations for use in mouth and pharyngeal therapeutics; pharmaceuticals for use as muscle relaxants; pharmaceuticals for the treatment of addiction to narcotics; pharmaceuticals for use in neuropathology; ophthalmic pharmaceuticals for treating blindness, conjunctivitis, cataract, glaucoma, retinal detachment, stye, chalazion, dacryoadenitis, corneal clouding, keratitis, gasserian ganglionitis, vitreous opacity, amaurosis, retinopathy, central retinal artery occlusion, retinoblastoma, melanoma, optic neuritis, optic nerve atrophy; pharmaceuticals for use osteoporosis and calcium metabolism modification; pharmaceuticals for the treatment of Parkinson's Disease and disturbances of the extrapyramidal system; pharmaceuticals for psychotropic, rhinologic and sinositic purposes; pharmaceuticals functioning as roborants and tonics; pharmaceuticals for use in thyroidal therapeutics; pharmaceuticals functioning as spasmolytics and inhibitors of thrombocyte aggregation; pharmaceuticals for the treatment of tuberculosis; pharmaceuticals functioning as alternants, urologics and venous agents; vitamins; pharmaceuticals for use as cytostatics and antineoplastic agents; homeopathic remedies, and medical plastics, namely sanitary preparations | SECTION 8 - CANCELLED | — |
| 009 | Scientific, electronic, photographic, optical, measuring, signaling and controlling apparatus and instruments, namely, analytical devices comprising polynucleotides, polypeptides or polynucleotides and polypeptides as detection means; magnetic data medium, namely tapes, discs, diskettes and CDs, preferably containing sequence data on polynucleotides, polypeptides or polynucleotides and polypeptides; computers; computer software for designing target specific polynucleotides and polypeptides and software for use in the field of synthesis of nucleic acids and peptides, proteins and control of synthesis machines | SECTION 8 - CANCELLED | — |
| 042 | Research and product development services for others in the filed of veterinary medicine, human medicine and agriculture; research and product development for others in the science and medical industries; computer services, namely, designing programs for others in data processing; chemistry consultation; biology consultation; biochemistry consultation; biotechnology consultation; gene technologies consultation; molecular biology consultation; pharmaceutical advice; medical services, veterinary services | SECTION 8 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by NOXXON Pharma
- Other trademarks owned by NOXXON Pharma
- Other trademarks owned by NOXXON Pharma
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 042
- Similar marks named MIRROR IMAGE
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 17, 2009 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| May 28, 2008 | CFIT | CASE FILE IN TICRS | — |
| Oct 24, 2007 | CORV | REVIEW OF CORRESPONDENCE COMPLETE | — |
| Oct 18, 2007 | PAPER RECEIVED | — | |
| Sep 10, 2006 | CORV | REVIEW OF CORRESPONDENCE COMPLETE | — |
| Jun 18, 2004 | PAPER RECEIVED | — | |
| Mar 11, 2003 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Dec 17, 2002 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 27, 2002 | NPUB | NOTICE OF PUBLICATION | — |
| Sep 16, 2002 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 9, 2002 | CNEA | EXAMINERS AMENDMENT MAILED | — |
| May 28, 2002 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 28, 2002 | PAPER RECEIVED | — | |
| May 22, 2002 | 1.BD | Sec. 1(B) CLAIM DELETED | — |
| May 22, 2002 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 26, 2001 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 16, 2001 | DOCK | ASSIGNED TO EXAMINER | — |